MSH|^~\&|Reports|CML||23261|200507141041-500||ORU^R01||1|2.3PID|1|L44-1142||3367831780^YN^ON|LDPW^SCINIASL||19310508|M|||||9094574676ORC|NW|CC63171|||F|||||||181655^DMSODR EGDELRARCA RLDGO |||20040713OBR|1|CC63171||111F^GLUCOSE FASTING||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|3009^GLUCOSE FASTING|CHEMISTRY^^|6.0|MMOL/L|3.3-6.1||||F||303^1003009||70OBR|2|CC63171||067^CREATININE||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|3180^CREATININE|CHEMISTRY^^|81|UMOL/L|60-127||||F||303^1003180||70OBR|3|CC63171||252^URIC ACID (URATE)||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|3200^URATE|CHEMISTRY^^|304|UMOL/L|180-450||||F||303^1003200||70OBR|4|CC63171||226^SODIUM||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|3210^SODIUM|CHEMISTRY^^|140|MMOL/L|135-146||||F||303^1003210||70OBR|5|CC63171||204^POTASSIUM||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|3220^POTASSIUM|CHEMISTRY^^|4.4|MMOL/L|3.5-5.2||||F||303^1003220||70OBR|6|CC63171||053^CHLORIDE||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|3230^CHLORIDE|CHEMISTRY^^|100|MMOL/L|95-108||||F||303^1003230||70OBR|7|CC63171||222^SGOT (AST)||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|3370^AST|CHEMISTRY^^|30|U/L|6-42||||F||303^1003370||70OBR|8|CC63171||191^PHOSPHATASE ALKALINE||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|3360^ALK PHOS|CHEMISTRY^^|56|U/L|30-110||||F||303^1003360||70OBR|9|CC63171||030^BILRUBIN TOTAL||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|3340^TOTAL BILIRUBIN|CHEMISTRY^^|10.0|UMOL/L|0.0-23.0||||F||303^1003340||70OBR|10|CC63171||117^HDL/LDL||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|3120^CHOLESTEROL|CHEMISTRY^^|4.19|MMOL/L|TARGET <5.20||||F||365^1003120||70OBX|2|ST|3140^TRIGLYCERIDES|CHEMISTRY^^|2.84|MMOL/L|TARGET <1.71|A|||F||365^1003140||70OBX|3|ST|3923^HDL CHOLESTEROL|CHEMISTRY^^|0.76|MMOL/L|TARGET >1.29|A|||F||365^1003923||70NTE|1|L|NOTE:  NEW REFERENCE RANGEOBX|4|ST|3933^LDL CHOLESTEROL|CHEMISTRY^^|2.14|MMOL/L|SEE TARGETS||||F||365^1003933||70NTE|1|L|NOTE:  NEW REFERENCE RANGEOBX|5|ST|3939^CHOL/HDL RATIO|CHEMISTRY^^|5.51||SEE TARGETS|A|||F||365^1003939||70NTE|1|L|CLINICAL RISK STATUS AND TARGET LIPID LEVELSNTE|2|L|*********************************************NTE|3|L|   RISK   : LDL-C --TARGETS-- CHOL/HDL RATIONTE|4|L|    LOW   : <4.50     AND       <6.0NTE|5|L| MODERATE : <3.50     AND       <5.0NTE|6|L|   HIGH   : <2.50     AND       <4.0NTE|7|L| AS PER OAML GUIDELINES CLP-017OBR|11|CC63171||5050^URINALYSIS-ROUTINE||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|5005^APPEARANCE|URINALYSIS^^ROUTINE:|CLEAR||||||F||510^1005005||70OBX|2|ST|5010^COLOUR|URINALYSIS^^ROUTINE:|YELLOW||||||F||510^1005010||70OBX|3|ST|5015^PH|URINALYSIS^^ROUTINE:|6.5||5.0-9.0||||F||510^1005015||70OBX|4|ST|5020^PROTEIN|URINALYSIS^^ROUTINE:|NEGATIVE|G/L|NEGATIVE||||F||510^1005020||70OBX|5|ST|5025^GLUCOSE|URINALYSIS^^ROUTINE:|NEGATIVE|MMOL/L|NEGATIVE||||F||510^1005025||70OBX|6|ST|5030^KETONE|URINALYSIS^^ROUTINE:|NEGATIVE|MMOL/L|NEGATIVE||||F||510^1005030||70OBX|7|ST|5040^BLOOD|URINALYSIS^^ROUTINE:|NEGATIVE||NEGATIVE||||F||510^1005040||70OBX|8|ST|5045^NITRITE|URINALYSIS^^ROUTINE:|NEGATIVE||NEGATIVE||||F||510^1005045||70OBX|9|ST|5046^LEUKOCYTE ESTERASE|URINALYSIS^^ROUTINE:|NEGATIVE||NEGATIVE||||F||510^1005046||70OBX|10|ST|5055^SPECIFIC GRAVITY|URINALYSIS^^ROUTINE:|1.022||||||F||510^1005055||70OBR|12|CC63171||393^COMPLETE BLOOD COUNT||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|2010^HEMOGLOBIN|HEMATOLOGY^^|115|G/L|135-180|A|||F||201^1002010||70OBX|2|ST|2013^HEMATOCRIT|HEMATOLOGY^^|0.370|L/L|0.37-0.54||||F||201^1002013||70OBX|3|ST|2016^WBC COUNT|HEMATOLOGY^^|7.7|X10 9/L|4.0-11.0||||F||201^1002016||70OBX|4|ST|2019^RBC COUNT|HEMATOLOGY^^|5.27|X10 12/L|4.50-6.50||||F||201^1002019||70OBX|5|ST|2022^MCV|HEMATOLOGY^^|70.2|FL|80-97|A|||F||201^1002022||70OBX|6|ST|2025^MCH|HEMATOLOGY^^|21.8|PG|27.0-32.0|A|||F||201^1002025||70OBX|7|ST|2028^MCHC|HEMATOLOGY^^|310|G/L|320-360|A|||F||201^1002028||70OBX|8|ST|2029^RDW|HEMATOLOGY^^|14.8|%|11.0-14.5|A|||F||201^1002029||70OBX|9|ST|2030^PLATELET COUNT|HEMATOLOGY^^|211|X10 9/L|150-400||||F||201^1002030||70OBX|10|ST|2191^ABSOLUTE:  NEUTROS|HEMATOLOGY^^|4.6|X10 9/L|2.0-7.5||||F||201^1002191||70OBX|11|ST|2193^     (A)   LYMPH|HEMATOLOGY^^|1.9|X10 9/L|1.1-3.3||||F||201^1002193||70OBX|12|ST|2196^     (A)   MONO|HEMATOLOGY^^|0.9|X10 9/L|0.0-0.8|A|||F||201^1002196||70OBX|13|ST|2197^     (A)   EOS|HEMATOLOGY^^|0.3|X10 9/L|0.0-0.5||||F||201^1002197||70OBX|14|ST|2198^     (A)   BASO|HEMATOLOGY^^|0.0|X10 9/L|0.0-0.2||||F||201^1002198||70OBX|15|ST|2083^HYPOCHROMIA|HEMATOLOGY^^|MILD|||A|||F||203^1002083||70OBX|16|ST|2086^MICROCYTOSIS|HEMATOLOGY^^|1+|||A|||F||203^1002086||70OBX|17|ST|2095^OVALOCYTES|HEMATOLOGY^^|FEW||||||F||203^1002095||70OBX|18|ST|2098^POLYCHROMASIA|HEMATOLOGY^^|SL INCREASED|||A|||F||203^1002098||70OBX|19|ST|2101^TARGET CELLS|HEMATOLOGY^^|FEW||||||F||203^1002101||70OBX|20|ST|2111^PLATELETS|HEMATOLOGY^^|NORMAL||||||F||203^1002111||70OBR|13|CC63171||445^PROTHROMBIN TIME||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|2165^  I.N.R.|HEMATOLOGY^^COAGULATION|5.2||0.8-1.2|A|||F||235^1002165||70NTE|1|L|                          NTE|2|L|      RECOMMENDED I.N.R. RANGENTE|3|L|------------------------------------NTE|4|L|THROMBOEMBOLISM RISK       2.0 - 3.0NTE|5|L|PROSTHETIC HEART VALVE     2.5 - 3.5NTE|6|L|                       OBR|14|CC63171||341^SENSITIVE TSH||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|4025^TSH|RIA^^|1.39|MU/L|0.30-4.70||||F||401^1004025||70OBR|15|CC63171||339^T4 FREE||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|4032^T4 FREE|RIA^^|15.7|PMOL/L|9.1-23.8||||F||401^1004032||70OBR|16|CC63171||329^FERRITIN||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|4050^FERRITIN|RIA^^|26|UG/L|27-220|A|||F||402^1004050||70OBR|17|CC63171||345^VITAMIN B12||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|4035^VITAMIN B12|RIA^^|142|PMOL/L|>131||||F||402^1004035||70OBR|18|CC63171||309^RBC FOLATE + HCT||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|4045^RBC FOLATE|RIA^^|1039|NMOL/L|>372||||F||402^1004045||70OBR|19|CC63171||700^DOCUMENTATION FEE||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBR|20|CC63171||634^CULTURE URINE CAL. LOOP QUAN||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|61051^STATUS|^MICROBIOLOGY^CLEAN CATCH URINE|FINAL||||||F||6100^1061051||70OBX|2|ST|61061^CULTURE REPORT|^MICROBIOLOGY^CLEAN CATCH URINE|||||||F||6100^1061061||70NTE|1|L|NO GROWTHOBR|21|CC63171||800^BLOOD FILM INTERPRETATION||20040713|20040713|||||||||181655^DMSODR EGDELRARCA RLDGO |||||||||FOBX|1|ST|2112^BLD FILM EXAM|HEMATOLOGY^^|||||||F||221^1002112||70NTE|1|L|THERE IS HYPOCHROMIC MICROCYTIC ANEMIA.NTE|2|L|RULE OUT IRON DEFICIENCY, THALASSEMIANTE|3|L|RECOMMEND:  SERUM FERRITINNTE|4|L|            HEMOGLOBIN ELECTROPHORESISNTE|5|L| NTE|6|L|DR A SEIDENFELDFTS|1